Position TitleAssociate Professor
Karmanos Cancer Institute
Elliman Building, RM - 3128
421 E Canfield
Detroit, MI 48201
(1998) Ph.D., Jilin University, Changchun, China
(1995) M.S., Jilin University, Changchun, China
(1992) B.S., Jilin University, Changchun, China
(2002-2004) Research Associate, Barbara Ann Karmanos Cancer Institute, Wayne State University School of Medicine, Detroit, MI
(1999-2002) Postdoctoral Fellow, Barbara Ann Karmanos Cancer Institute, Wayne State University School of Medicine, Detroit, MI
(1998-1999) Postdoctoral Fellow, Department of Biochemistry, University of Queensland, Brisbane, Australia
(2014-Present) Associate Professor (Tenure), Department of Oncology, Wayne State University School of Medicine, Detroit, MI
(2008-Present) Adjunct Professor, College of Life Science, Jilin University, Changchun, China
(2010-2014) Assistant Professor, Department of Oncology, Wayne State University School of Medicine, Detroit, MI
(2007-2010) Assistant Professor, Department of Pediatrics, Wayne State University School of Medicine, Detroit, MI
(2004-2007) Assistant Professor, Wayne State University School of Medicine, Detroit, MI
Hopsital and Other Professional Appointments
(2004-Present) Member, Barbara Ann Karmanos Cancer Institute, Detroit, MI
Major Professional Societies
Member: American Association for Cancer Research
Active member: American Society of Hematology
Honors and Awards
(2008) Center Director's Quarterly Research Award, Karmanos Cancer Institute
(2007) Faculty Research Excellence Award, Wayne State University School of Medicine
(2004) Chareles J. Epstein Research Award, the National Down Syndrome Society
(2003) Chareles J. Epstein Research Award, the National Down Syndrome Society
(1994) The second prize for The Second China Grand Prix of the Invention of Applied Sciences & Technology for University Students, Beijing, P.R.China
CB 7210: Fundamentals of Cancer Biology
CB 7240: Cancer Chemotherapy
CB 7300 F31: Special Topics in Cancer Biology - Grant Writing
CB 7700: Recent Developments in Cancer Biology
Research in the Ge laboratory spans the basic biology and development of acute leukemia in children, to combinational therapies and translational studies with primary patient specimens. Studies of the Ge laboratory have concerned the biology of critical transcription factors such GATA1, ETS2, and RUNX1 in AML, including identification of high frequency RUNX1-ETO fusion protein isoforms as determinants of chemosensitivity and leukemogenesis and determination of the roles of GATA1 and EST2 in the biology and chemotherapy responses in a specific subtype of AML, acute megakaryocytic leukemia (AMkL) by using clinically relevant cell lines and diagnostic AML blasts. Most recent studies have been focusing on the molecular basis for the remarkable synergism between histone deacetylase (HDAC) inhbitors (HDACIs) and standard chemotherapy drugs used for treating AML, neuroblastoma, and pancreatic cancer.
1. Qi W, Zhang W, Edwards H, Chu R, Taub JW, Wang Z, Wang Y, Li C, Lin H, and Ge Y. Synergistic anti-leukemic interactions between panobinostat and MK-1775 in acute myeloid leukemia ex vivo. Cancer Biol Ther. 2015; 16: 1784-1793.
2. Shaham L, Vendarmini E, Ge Y, Goren Y, Tijssen M, Birger Y, McNulty M, Geron I, Schwartzman O, Goldberg L, Chou ST, Pitman H, Weiss MJ, Michaeli S, Sredni B, Göttgens B, Crispino J, Taub JW, and Izraeli S. MiR-486-5p is an oncomiR in the myeloid leukemias of Down Syndrome. Blood. 2015; 125: 1292-1301.
3. Xie C, Edwards, Caldwell JT, Wang G, Taub JW, and Ge Y. Obatoclax potentiates the cytotoxic effect of cytarabine on acute myeloid leukemia cells by enhancing DNA damage. Mol Oncol. 2015; 9: 409-421.
4. Wang G, Niu X, Zhang W, Caldwell JT, Edwards H, Chen W, Taub JW, Zhao L, and Ge Y. Synergistic antitumor interactions between MK-1775 and panobinostat in preclinical models of pancreatic cancer. Cancer Lett. 2015; 356: 656-668.
5. Hanmod S, Wang G, Edwards H, Buck SA, Ge Y, Taub JW, and Wang Z. Targeting histone deacetylases (HDACs) and wee1 for treating high-risk neuroblastoma. Pediatr Blood Cancer. 2015; 62: 52-59.
6. Wang G, Chen S, Edwards H, Cui X, Cui L, and Ge Y. Combination of chloroquine and obatoclax results in synergistic cytotoxicity against pancreatic cancer cells. Oncol Rep. 2014; 32: 2789-94.
7. Qi W, Xie C, Li C, Caldwell JT, Edwards H, Taub JW, Wang Y, Lin H, and Ge Y. CHK1 plays a critical role in the anti-leukemic activity of the wee1 inhibitor MK-1775 in acute myeloid leukemia cells. J Hematol Oncol. 2014; 7(1):53.
8. Caldwell JT, Edwards H, Buck SA, Ge Y, and Taub JW. Targeting the wee1 Kinase for Treatment of Pediatric Down Syndrome Acute Myeloid Leukemia. Pediatr Blood Cancer. 2014; 61: 1767-1773. [Featured on the cover for the issue].
9. Chen S, Wang G, Niu X, Zhao J, Tan W, Wang H, Zhao L, and Ge Y. Combination treatment with AZD2281 (Olaparib) and GX15-070 (Obatoclax) results in synergistic antitumor activities in preclinical models of pancreatic cancer. Cancer Lett. 2014; 348: 20-28.
10. Niu X, Wang G, Wang Y, Caldwell JT, Edwards H, Xie C, Taub JW, Li C, Lin H, and Ge Y. Acute myeloid leukemia cells harboring MLL fusion genes or with the acute promyelocytic leukemia phenotype are sensitive to the Bcl-2 selective inhibitor ABT-199. Leukemia. 2014; 28:1557-1560.